{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Sagimet Biosciences Inc."},"Symbol":{"label":"Symbol","value":"SGMT"},"Address":{"label":"Address","value":"155 BOVET ROAD,SUITE 303, SAN MATEO, California, 94402, United States"},"Phone":{"label":"Phone","value":"650-561-8600"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California."},"CompanyUrl":{"label":"Company Url","value":"https://www.sagimet.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Anne-Marie O'Farrell","title":"Senior Vice President-Research & Development"},{"name":"David A. Happel","title":"President, Chief Executive Officer & Director"},{"name":"Eduardo Bruno Martins","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}